Market Overview

UPDATE: Jefferies Initiates AbbVie at Buy on Growth Outlook, High Yield

Related ABBV
AbbVie's VIEKIRAX Approved in Japan for the Treatment of Genotype 1 Chronic Hepatitis C
AbbVie Initiates Pivotal Phase 3 Study of Veliparib for Patients with Early-Stage Triple-Negative Breast Cancer
Amgen Invites AbbVie To Dance For Humira Biosimilar (Seeking Alpha)

Jefferies initiated coverage on AbbVie (NYSE: ABBV) with a Buy rating and a $44.00 price target.

Jefferies commented, "AbbVie is our top pick for 2013. We see the initial trading volatility post-spin as an opportune entry point into the shares as we soon expect income funds to work the dividend yield down to at least the 4.0% level. A more durable long-term performance from Humira, stronger pipeline delivery and operating margin expansion drive our cash EPS estimates up to 22% ahead of consensus."

AbbVie closed at $34.09 on Tuesday.

Latest Ratings for ABBV

Nov 2015Morgan StanleyUpgradesEqual-weightOverweight
Sep 2015CitigroupUpgradesNeutral
Jul 2015Deutsche BankMaintainsBuy

View More Analyst Ratings for ABBV
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Initiation Pre-Market Outlook Analyst Ratings


Related Articles (ABBV)

View Comments and Join the Discussion!

Get Benzinga's Newsletters